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Abstract 
Background: There is strong evidence to show that antiretroviral therapy (ART) 
improves the survival and quality of life of people living with HIV/AIDS (PLWHA). 
Namibia, one of the countries hardest hit by HIV/AIDS, has embarked on a large 
scale public sector roll out of ART. The Catholic Health Services is implementing an 
HIV/AIDS treatment program in Nyangana rural district, home to 41,000 people with 
an HIV seroprevalence (ANC, 2006) of 12%. Aim: This study aims to analyse the 
clinical and immunological responses and survival pattern of HIV/AIDS patients 
receiving ART in Nyangana District. Objectives: To establish the ART coverage and 
demographic characteristics of eligible PLWHA in Nyangana district, to describe 
baseline clinical profile and subsequent clinical response of HIV/AIDS patients 
receiving ART and to determine baseline immunological profile and the trend of CD4 
count response from baseline to different follow up periods. Study design: This is a 
quantitative, cohort analysis study of routine clinical data, reviewing patients’ records 
retrospectively. Population and sample: This was a census of all patients that started 
ART in the district between August 2004 and April 2006. Data collection process: 
Standardised patient files and registers were used to abstract data as per selected 
variables into an Excel database. Data analysis: Epi Info and SPSS were used. A 
cohort analysis was done using descriptive and analytic statistics to determine basic 
characteristics, overall treatment outcome, survival analysis (KM, Cox regression), 
paired comparison to determine change in weight and CD4 cell count pre and post-
ART. Results: ART is currently reaching 46% of PLWHA in need of it in Nyangana 
District. At baseline, the mean age was 36 years, mean weight was 48 kg and median 
CD4 cell count was 131 cells/µL (IDR: 75-216). Females represented 69% of 
patients, were more likely to have higher CD4 count at baseline (p<0.0001) and more 
likely to survive compared to males (OR: 2.3). The mean duration on ART was 20.8 
and 5.1 months, respectively, for those still alive and those who died. A mortality rate 
of 23.5% occurred mainly in the first 3 months of initiation (60%) with TB (37.9%) 
and gastroenteritis (18.2%) as leading causes of death. Patients with lower body 
weight and poor functional status were less likely to survive (OR: 0.9 and 0.4) and 
those who died were twice as likely to have fair to poor self-reported adherence 
(p=0.008). Survival at 24 months was 75%. 
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Chapter 1. Introduction 
 
It is now common knowledge that HIV/AIDS is the worst epidemic to hit the world in 
the history of mankind. To date, HIV/AIDS has decimated more people than all the 
wars known in human history. AIDS is killing close to 2.5 million each year. This is 
translated into more than 6,000 lives robbed per day with devastating human, 
economic and social impact. Yet the trend of new infections continues unabated. 
Every day 6,800 new infections occur fuelling the current estimate of 33.2 millions 
people living with HIV worldwide (UNAIDS, 2007). 
 
Sub-Saharan Africa (SSA) is particularly hard hit with the highest disease burden . Of 
the total PLWHA, SSA is harbouring 68% of adults and 90% of children. 
Consequently, 78% of AIDS death in 2007 occurred in this region. However, the 
picture in SSA varies significantly across regions with southern Africa displaying the 
worst epidemic pattern. The Southern African Development Community (SADC) is 
home to the top 10 highest HIV prevalence rates in the world with Swaziland 39%, 
Botswana 32%, South Africa 29%, Lesotho 21%, Namibia 19.9% and Zimbabwe 
18%. This region was estimated to have 32% of all new infections and AIDS death 
globally in 2007(UNAIDS, 2007). 
 
In as much as this epidemic has been the worst ever recorded, the global response to 
it, by means of prevention, treatment, care and support services has equally been the 
biggest public health intervention ever undertaken in living memory (Venter, 2005; 
UNAIDS, 2004). In particular, the introduction of Highly Active Antiretroviral 
Therapy (HAART) during the Vancouver international conference in 1996 has 
changed the landscape of HIV/AIDS the world over. HIV/AIDS was turned from a 
death sentence to a chronic manageable disease for most patients in developed 
countries (Pomerantz, 2001). Several studies were later conducted on how to 
implement HAART in resource-constrained settings based on the WHO scaling up 
strategies. Most of these studies have demonstrated the benefit of improved quality of 
life, prolonged survival, regained dignity and a return to productive life for PLWHA 
receiving HAART. 
 
 
 
 
 2 
The Namibian estimate of approximately 230,000 People Living With HIV/AIDS 
(PLWHA) out of a total population of 1.8 million (MoHSS, 2006; Census, 2001) 
means considerable health expenditure for the Government, misery and death for an 
increasing number of people if access to life saving drugs is not secured. Since 1996, 
HIV/AIDS is the leading cause of death in Namibia. An estimated 17,000 Namibian 
died of AIDS in 2005 (MoHSS, 2006). With help from development partners, the US 
President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund 
(GFATM), the Namibian Ministry of Health and Social Services (MoHSS) initiated 
its treatment program in 2003 and by end of 2007 more than 30,000 were on HAART. 
Amongst other partners in the field, the Catholic Church in Namibia (second biggest 
public health provider after the MoHSS), fulfilling its mission of care, is running a 
treatment program funded by PEPFAR through USAID. This program covers 4 rural 
district Hospitals and provides care for just over 10% (3,500) of current ARV users in 
the country.  
 
Nyangana Mission Hospital is one of the 4 districts that started the treatment program 
in August 2004. It was selected for this analysis based on completeness and timely 
reporting pattern of its ART clinic. As of end of April 2007, 590 PLWHA were 
enrolled on HAART in this catchment area of 41,000 population. However, 
longitudinal documentation and analysis of clinical recovery and immunological 
restoration of these patients have not yet been done. This knowledge gap is not only 
observed within Catholic Health Services (CHS) but also throughout the country. A 
sustained clinical and immunological response to ART is dependent on several factors 
stemming from the regimen potency to individual factors such as adherence, clinical 
baseline characteristics, disease stage (clinical and CD4 count). The need to conduct 
such cohort analysis in order to evaluate and enhance the program performance and 
effectiveness is critically felt amongst most ART program managers across the 
country. This study would be one of the first local attempts of its kind for the Catholic 
Mission Hospitals in Namibia and would be hopefully replicated in a multi-centre 
approach. 
Problem statement 
The introduction of ART has dramatically changed the course of HIV disease with 
many studies demonstrating its efficacy worldwide. The reduction in morbidity and 
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mortality for HIV/AIDS patients on ART is unquestionable. However, apart from 
amazing individual stories of treatment success across all ART sites, there is very 
limited longitudinal documentation and analysis of ARV treatment response in 
Namibia. This knowledge gap, in spite of the ongoing rapid countrywide roll out, is 
indicative of not only the infancy stage at which the ART program is still in Namibia 
but also the insufficient use of the ART Management Information System (MIS) in a 
systematic research agenda. Given the variability of patient characteristics, are our 
patients on ART responding in the same way as described elsewhere? The 
effectiveness of the Nyangana ART program will be evaluated using routine data that 
provides evidence of treatment success based mainly on clinical and immunological 
responses, and survival analysis.  
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Chapter 2. Literature review 
 
Since the discovery of the first case of HIV more than two decades ago, thousands of 
publications have inundated the literature. This review will look at some of the papers 
(published or otherwise) dealing with HAART programs in general and the analysis 
of cohort studies in particular. 
 
In a context of evaluation of programme effectiveness, it helps to know what we 
understand by that. According to Katzenellenbogen, Joubert and Karim (1997), 
effectiveness, as a measure of outcome, is defined by how well a process or health 
intervention is working. They go on to argue that “health planners seek measures of 
effectiveness to establish whether health care interventions achieve their stated 
objectives…” Since the late nineties, several studies have been done on the  
effectiveness of ART in resource-poor settings. The evaluation of ART programme 
effectiveness will be at the centre of our discussion throughout this review. 
 
2.1. The Highly Active Antiretroviral Therapy: HAART 
Prior to HAART era, HIV infection progressed to AIDS with a subsequent average of 
2 years between the onset of AIDS to death as illustrated by the figure 1 below. The 
disease would take its natural course without faltering with most health care facilities 
becoming places of death especially in developing countries where poverty and lack 
of food security compounded survival with HIV/AIDS.  
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It is common knowledge that in 1996, the Vancouver 11th International AIDS 
conference rose to the AIDS challenge when a number of presentations were made 
announcing the introduction of a triple combination of ARV drugs. These 
combinations aimed at reducing HIV replication sufficiently, restoring immune 
deficiency to safe levels and improving the quality and prolonging the lives of 
PLWHA. A death sentence was commuted into a chronic manageable disease or 
chronic non-curable infection (Marquez, 2004). The advent of new classes of ARV 
drugs and their use in combination was the breakthrough that established this 
combination as gold standard of evidence-based care (WHO, 2002).  
 
There are 3 main classes of antiretroviral agents, one of them forming the backbone of 
any combination: the Nucleoside reverse Transcriptase Inhibitors (NRTI). Two drugs 
of this class (dual NRTI) are complemented by a third drug form either a Non-
Nucleoside Reverse Transcriptase Inhibitor (NNRTI) or a Protease Inhibitor (PI) 
class. The combination of at least one drug from each class, and preferably 2 NRTI  
(backbone) and 1 NNRTI, constitutes what is commonly called Highly Active 
Antiretroviral Treatment (HAART). Additional classes are coming on the market and 
comprise Nucleotide reverse transcriptase inhibitors (NtRTI), Fusion inhibitors, 
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integrase inhibitors and CCR5 inhibitors. Many of these drugs are still experimental 
and out of reach for most developing countries. 
 
The goals of therapy with these combinations referred to as HAART do not differ 
from developed to resource constrained settings. They are summarised as an 
improvement in quantity and quality of life by reducing HIV related morbidity and 
mortality through maximal and durable viral suppression and restitution and/or 
safeguarding of immunological function (Guidelines for Antiretroviral Therapy in 
Adults, 2005). 
 
As acknowledged in many studies, some of the major challenges in ART provision 
are fundamentally an unparalleled commitment to a life long therapy, with need for 
the highest adherence ever achieved in any chronic medication (>95% of compliance 
to achieve optimal viral suppression)(Wilson et. al., 2002; WHO, 2006), development 
of side effects (seldom fatal but can affect adherence) and the cost (medications, 
clinical and laboratory monitoring). It is therefore a recommendation in most 
guidelines that ARV therapy never be initiated as an emergency (except in post 
exposure prophylaxis and in case of Kaposi Sarcoma) (MoHSS, 2007). It should not 
be started unless patients are fully prepared and ready for a life long commitment. 
This readiness includes comprehensive adherence counselling and treatment of 
opportunistic infections prior to initiating ART. 
  
2.2. The scaling up and accessibility of treatment programs 
The demand for access to ART in developing countries was a fight for human rights. 
This followed the increasing frustrations on the fact that rich nations were giving 
access to their AIDS patients while the poor ones were told to be content with scaling 
up prevention efforts because of cost constraints and/or complexity of treatment 
regimens. In 2003, only 2% of those in need of treatment in Africa were accessing it 
(WHO, 2003; UNAIDS, 2004). Although there is no successful treatment program 
without serious prevention efforts, many advocacy groups could not allow this 
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injustice to continue as they argued rightly that “treatment and prevention are two 
sides of the same coin” (WHO, 2003). 
 
From Professor Harries’ statement in 1999, when he declared to an international 
gathering (Regional American IUATLD Conference in Chicago in February 1999) 
that “ART cannot be provided to Sub-Saharan Africa” to this day, a long, painful and 
joyful road has been traveled. Events happily proved him totally wrong as he later 
championed access to ART in Malawi and several research findings demonstrated that 
the provision of high quality HAART is feasible in resource-limited settings using the 
WHO public health approach (WHO, 2006). Most patient outcome such as clinical 
results, retention in care, adherence, mortality and loss to follow up (defaulters) are 
comparable to findings in the literature both for similar settings and for the developed 
world (MSF, 2004). 
 
By now, most developing countries have introduced the ART program although 
hastily implemented and mainly in a vertical approach. This follows the dramatic drop 
in prices of ARV and other related commodities and a huge influx of international 
donor funds either through Global Fund with “3 by 5” initiative or through PEPFAR 
with “2/7/10” strategy (WHO, 2003). According to the latest WHO report (2007), the 
coverage of HIV treatment is now reaching 28% of PLWHA in need of it worldwide 
from 8% in 2003 (Keith, 2007). Although this is a positive development, it is still a 
long way from the 2010 goal of universal access. 
 
Access to treatment varies with gender. In Europe, intake is male dominated as the 
epidemic is driven and fuelled by men having sex with men and intravenous drug 
users (Sabin, 2003) whereas many African cohorts reveal that up to 75% or more of 
patients are females (Bekker, 2004; Venter, 2004). In a cohort analysis of a pilot 
programme to assess the efficacy of triple therapy for PLWHA in a multi-centre study 
(Namibia, Botswana, Lesotho, South Africa), the Bristol Myers Squib (BMS, 2006) 
team presented similar patterns of sex distribution ranging from 33.1% to 36.1% of 
males enrolled on ART. In the treatment program of the CHS in Namibia, the 
situation is not any different as revealed in their reporting with currently 35% of about 
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4,500 on ART being males (CHS, 2007). Venter (2004) argues that this 
“feminisation” of the epidemic with unfavourable male entry to care is largely 
attributed to poor health seeking behaviour and high stigma amongst males but also to 
activities of Prevention of Mother to Child Transmission (PMTCT) program offering 
an active case finding for HIV positive women. Obviously other factors are also 
identified such as the higher rate of infection in females and the reported male 
unfriendly settings of many VCT centres in the Mission facilities. The introduction of 
Maternal and Child Health activities (ANC and vaccination activities), meant to 
destigmatise the sites, has created another problem of men feeling out of place, 
stepping in only at time of extreme desperation and when they are already very sick. 
Overcoming this barrier is one of the biggest challenges of many ART programs. 
However, anecdotal data from the private sector in Namibia indicate more men than 
women accessing ART. Reasons for this seem to be mainly related to privacy. The 
private sector offers more privacy than public hospitals and men in need of treatment 
would readily go there if they are covered by their medical aid scheme. 
 
The access to treatment in Namibia looks like a success story. According to the 
Namibian Minister of Health and Social Services (MoHSS) quoted in a speech by a 
newspaper (The Namibian, 2005), as of December 2005, Namibia had close to 18,000 
patients on ART of which 10% were from the CHS Mission facilities. This effectively 
put Namibia among only three SSA countries, the other 2 being Uganda and 
Botswana, to have provided ART to more than 25% of those in need of it. Models 
such as Spectrum have been developed to estimate the number of PLWHA who are 
eligible for ART based on variables such as adult HIV prevalence produced by the 
Estimation and Projection Package (EPP), proportion of PLWHA who are immune 
suppressed, consequences of the HIV/AIDS epidemic, including new infections, 
mortality as well as impact of treatment on survival  (Stover et al, 2006). 
 
For those on treatment, the fundamental question is how well they are doing since 
improved access to treatment is not necessarily synonymous with good quality of 
care.  
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2.3. Cohort analysis in ART programmes 
The basic departing point of our investigation of the HAART programme is aligned 
on identifying the following: who are we serving (socio-demographic characteristics), 
how are we serving them (quality), for what results (response/outcome).  
 
The use of simplified cohort analysis to monitor ART patients and evaluate their 
treatment outcomes is a key WHO recommendation for patient monitoring systems. 
This approach is not equivalent to the cohort research design but rather refers to 
tracking a group of patients starting ART during a specified time period. Baseline 
characteristics will then be compared to the status at different follow up periods 
(WHO, 2006). Ultimately, to compare to other programs, derive lessons learned and 
disseminate evolving best practices in HAART, we must actively evaluate 
effectiveness and progress. 
 
The beneficial impact of ART on HIV related morbidity and mortality is not 
questionable anymore. Many European cohorts started earlier on demonstrated the 
successful use of ART. The only problem is that those findings were by western 
standards using different patient characteristics and readily available resources for 
viral loads and CD4 count testing and monitoring (Philipps, 2001; Egger, 2002). 
 
On the other hand, African cohort studies, once accessibility was secured through 
plummeting commodity prices and fund mobilisation, started showing that ordinary 
African men and women can also effectively benefit from ART without excessive 
toxicity (WHO, 2006). 
Goal of ART 
The goal of ARV therapy is to reduce viral load below assay detection limits. Our 
analysis of treatment effectiveness will be based on criteria for treatment success or 
failure as laid down in the Southern African HIV Clinicians Society Guidelines for 
ARV (2005) as well as in the WHO ART guideline (WHO, 2006). Limitation in the 
use of viral load in many developing countries, including Namibia, makes it difficult 
to monitor viral activity as a direct measure of the treatment success. The latter is best 
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measured by the decline in viral load of at least 1 log from pre-treatment levels after 
6-8 weeks of initiation of therapy or a “decline in viral load to <400 RNA copies by 
24 weeks after commencement of therapy”. However, in the absence of viral load, 
CD4 T-cell count, which measures the robustness of the immune system became, not 
only the most reliable proxy to determine prognosis, optimal time for therapy 
initiation, and monitoring but also a tool for assessment of effectiveness of ART. This 
is despite its measurement being approximate and with wide confidence intervals 
(Sheperd, Laeyendecker, Quinn, 2008). Therefore, criteria for ARV treatment failure 
will be based not only on virological failure but also and particularly in our resource-
constrained settings, on immunological and clinical failures. Clinical acumen and 
immunological monitoring remain the corner stone of ART delivery system in 
resource-constrained settings. 
 
WHO, 2006, defines immunological failure as a 50% drop in CD4 count from peak 
value or return to or fall to pre-ART baseline after 6 months of therapy or a CD4 
count < 100 cells after 6 months of therapy.  
 
Clinical failure is suggested by continued disease progression or development of new 
stage III or IV condition while on ART for more than 6 months. The clinical staging 
here refers to WHO classification of HIV-associated clinical disease. Patients are 
classified into stage I for those with asymptomatic disease, stage II for those with 
mild disease, stage III for those with advanced disease and stage IV for those with 
severe disease. This classification is recommended to form part of baseline 
assessment before entry into care and guide a number of decisions including initiation 
of cotrimoxazole prophylaxis and/or ART (WHO, 2006).  
 
In addition to this classification, performance scale and functional status are added to 
determine quality of life and productivity. ART clinics have been using performance 
scale in the past. However, recent WHO recommendations for patient monitoring 
system are in favour of the use of functional status which classifies patient according 
to their level of activity in three classes: Working (able to perform usual work in or 
out of the house, go to school or for children, normal activities or playing), 
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Ambulatory (able to perform activities of daily living but not able to work or play) or 
Bed ridden (not able to perform activities of daily living) (WHO, 2006).  In the best 
case scenario, given a correct clinical assessment, functional status always tallies with 
clinical stage resulting in patients of clinical stage III or IV falling under bedridden 
functional status. 
 
The combination of clinical and immunological parameters will constitute the basis of 
our cohort analysis as surrogate markers for monitoring treatment success. Of note is 
that these are not perfect surrogate markers because CD4 counts may rise in the 
presence of incomplete viral suppression or drug resistance and opportunistic 
infections may still occur despite excellent viral suppression and immunological 
recovery. These are drawbacks in resource limited settings without viral load testing 
facilities which represent the gold standard for monitoring ART success (WHO, 
2006). 
 
Patients’ characteristics and survival analysis 
In a study conducted by Weidle et al.(2002) in one of the first pilot ART site in Africa 
(Uganda), the findings in a total of 476 revealed that at the end of the pilot period, 248 
(52%) patients were still in care, 114 (24%) were lost to follow-up, 74 (16%) were 
known to have died, 17 (4%) were transferred out and were still receiving 
antiretroviral therapy, 14 (3%) discontinued antiretroviral therapy, and 9 (2%) had left 
the region. A different pattern of retention in care is seen in Malawi as Ferradini et al. 
(2006) results indicate that of 1,266 patients enrolled, 74% were still alive and on 
ART, 19% had died and 7% lost to follow up. It would appear that the mortality on 
HAART, which significantly affects the retention in care, varies widely between the 
4% of the ART-LINC collaboration and the 19% reported above (WHO, 2006). 
 
The median age at initiation of 37 years is observed in numerous studies: a European 
cohort described by Phillips (2001), a Namibian interim statistical analysis (BMS, 
2006) as well as an audit report in London (Sabin, 2003).  Considering the pattern of 
the epidemic hitting hard the most sexually active between 20-25 years, this appears 
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consistent with the natural HIV disease progress whereby the need for treatment only 
emerges after 10 years. 
 
In addition to women having better access to treatment, some findings suggest also a 
better treatment response as compared to men. Women present a profile of better 
baseline parameters and subsequently, at every time-point, invariably better 
virological and immunological response (Collazos, 2007). Though he acknowledges 
that it is less clear, Porter et al (2003), analysing some European cohort data, argued 
that the role of sex as a prognostic factor should be recognised as female injecting 
drug users seem to be at lower risk of death than do men in the same exposure 
category. 
 
Age is another prognostic factor. It was suggested in several studies, cited by Porter et 
al, that older people (more than 50 years) had poor short-term and long-term response 
to HAART. This was naturally attributed to the slow immune function reconstitution 
in elderly.  
 
With regards to clinical progression, our parameters of interest would be some 
selected and routinely available ones such as disease stage (as defined by WHO 
stage), performance scale or functional status (as defined by WHO) and weight. All 
these are measured at baseline and followed longitudinally to see the outcome during 
treatment. We know these are less reliable surrogate markers of treatment success but 
they are precisely what we have in most resource-poor settings. Until such a time that 
we are able to perform viral load, we have to rely heavily on CD4 cell count as well 
as selected clinical parameters such as weight gain to inform our decision on ART.  
The BMS, 2006, interim statistical analysis describes weight gain after 6 months on 
treatment and indicates that in different cohorts, the mean weight gain has been of 3.8, 
4.4, 5.8 and 6.2 kg in Botswana, South Africa, Namibia and Lesotho respectively. 
This is from a recorded baseline median weight varying from 55.4 to 61.2 Kg. The 
weight gain appears to be higher in the Khayelitsha study (MSH, 2003) which 
indicates the median weight gain at 6 and 12 months duration on ART to be at 5 kg 
and 9 kg respectively.  
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Body mass index (BMI) could also be used to monitor clinical outcomes. Moore et al 
(2007) indicate a baseline median BMI of 19.7 in a Ugandan study whereas Ferradini 
(2006) suggests that 33% of patients in his Malawian cohort had a baseline BMI < 
18.5. However, both of them did not provide the BMI progression or gain on follow 
up treatment to allow for comparability. 
 
Similarly, the Charadzulu case study (MSH, 2004), in an attempt to describe baseline 
clinical information of their cohort, categorized their study population per WHO 
staging as follows: 11.7% stage I, 15.6% stage II, 43.3% stage III, 12.6% stage IV and 
16.7% unspecified. A study in Uganda showed less severe immune suppression at 
baseline with 39% having WHO stage III or IV (Moore, 2007). However, in these two 
cases, there is no follow up data at subsequent time-points during therapy with which 
to document staging progression. The staging during therapy was a recent WHO 
recommendation and is termed T-staging. It uses, the same WHO standard staging 
adding “T” for patients on a minimum 6 months therapy.  The patient can be staged 
forwards (I to IV) when deteriorating (clinical failure) or backwards (IV to I) when 
improving (WHO, 2006).  
 
The median CD4 count at baseline depends on several factors and has varied since 
earlier days when ART was being made available to the current scale up stage. At the 
beginning of ART programme implementation, the median CD4 count used to be 
lower because people delayed seeking treatment until they were very ill and severely 
immunosuppressed. As the programme matures and HIV-positive people are screened 
earlier for ART the median CD4 count of people initiating ART increased closer to 
the value for ART eligibility. The Khayelitsha MSF study (Kasper et al., 2003) 
describes a median CD4 at baseline of 43 cells which has been increasing year-on-
year whereas the BMS multi-centre study indicates a median baseline of 85, 92, 109 
and 113 respectively in Lesotho, Namibia South Africa and Botswana cohorts. 
 
The data from Weidle et al.(2002) did not indicate the clinical recovery pattern but it 
concluded that patients with CD4 <50 cells were more likely to die than those with 
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CD4>50. This is consistent with most studies that underpin the predominant 
prognostic role of baseline CD4 count (Egger, 2002) in addition to low body weight, 
Tuberculosis and anaemia as other determinant factors (Theo, 2007). Furthermore, 
sex distribution on ART was not given although the authors put forward that there 
was no gender difference in treatment response, contradicting the view of Porter et al. 
cited above. 
 
However, the use of substandard regimens such as mono- and dual-therapies at the 
time of Weidle et al. (2002) study is likely to represent a serious caveat even if they 
asserted that virological and immunological responses to antiretroviral drugs were 
similar to those seen in North America and Europe. Despite the concern about early 
use of substandard regimens, many other studies including a meta-analysis by Ivers et 
al. (2005) underscore the fact that “ART treatment programs in resource-poor settings 
have efficacy rates similar to those reported for developed countries” though with 
significant differences between programs. In as much as we want to celebrate these 
findings, we still have to bear in mind that most programs in Africa are just over 4 
years old and still need long term follow up and review. 
 
In a Senegalese cohort analysing the trend of CD4 count recovery, Laurent et al. 
(2002) found out in a 58 treatment-naïve patients followed up that CD4 cell count 
rose by a median of 82, 147 and 180 cells/µL at months 6, 12 and 18, respectively. 
This finding is in keeping with what Bartlett and Gallant (2003) wrote:  
“The CD4 response is generally the mirror image of the RNA decay curve, with 
increases that average 50-60 cells…in the first 4 months with subsequent increases at 
a rate of ….50-100 cells…per year with good viral suppression.” 
However, other studies show a more pronounced increase at 6 months such as 85 
cells/µL in Charadzulu (MSF, 2004), 133 in Khayelitsha (MSH, 2003), whereas at 12 
months, the same studies documented respectively 178 and 221. Moreover findings 
from ART-LINC cohort that include both low and high income countries did not 
show difference in CD4 recovery pattern between the two settings. In conclusion, it 
would appear that, under normal circumstances, an increase of > 100 cells/µL in the 
first 6 to 12 months is a characteristic response of ARV naïve patients. According to 
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some WHO experts, given sufficient time, even patients with critically low CD4 count 
(<10 cells/µL) are likely to attain a successful CD4 count response. On the other 
hand, they argue that some patients may possibly never exceed 200 cells/µL and 
hence remain at high risk of severe immuno-suppression (WHO, 2006). 
 
Close monitoring and evaluation of program performance and impact assessment 
through longitudinal cohort analysis is needed. This will ensure a timely switch to 
second line therapy and prevent development and spread of a secondary HIV/AIDS 
epidemic with resistant strains.  
Aim 
This investigation, part of an ART program evaluation, is aimed at analysing the 
clinical and immunological response and survival of HIV/AIDS patients receiving 
HAART in the Nyangana Catholic Mission District in Namibia. 
 Objectives 
1. To estimate the ART coverage in Nyangana District 
2. To describe socio-demographic characteristics of eligible PLWHA enrolled in 
HAART in Nyangana District between August 2004 and April 2006 
3. To describe baseline (pre-ART) clinical profile and subsequent clinical 
response (selected clinical parameters) of the target patients population 
4. To determine baseline immunological profile and the trend of CD4 cell count 
response in the target patient population, from baseline to different follow up 
periods  
5. To determine baseline characteristics associated with survival and/or mortality 
of patients receiving HAART in Nyangana district during the period under 
study 
6. To make recommendations pertaining to case management and HAART 
program planning in the CHS HIV/AIDS program in order to improve patient 
outcome 
 
 
 
 
 16 
Chapter 3. Research Methodology 
3.1. Study design 
This is a quantitative, analytic cohort study, retrospectively examining clinical 
response, immunological restoration and overall treatment outcome (survival, death) 
of treatment naïve HIV/AIDS patients who have been enrolled on HAART during the 
period of August 2004 to April 2006 in Nyangana district.  
 
The choice of this method was justified by the fact that the investigator was using 
secondary routine data to conduct a longitudinal analysis of patients’ progression on 
HAART as part of an operational research on outcome evaluation. This is also in 
keeping with WHO recommendations on the patient monitoring system (WHO, 2006). 
A prospective cohort study would have been the ideal design but financial and time 
constraints were serious limiting factors. 
3.2. Population and settings 
This study will analyse secondary routine data (retrospective review of patient’s 
records) from the Nyangana ART clinic. This is a rural district of 41,000 catchment 
population with a 2006 ANC serosurveillance indicating 12% HIV prevalence. It is 
one of the four Catholic Mission facilities whose HIV treatment program was 
launched in August 2004. With an average monthly intake of 15 new patients, the 
clinic records show that as at end of 2006, 450 patients were receiving ART out of a 
total of 590 ever started. The observed attrition rate of 23.7% is mainly driven by the 
mortality on HAART which is one of the major challenges facing the programme. 
The investigator has access to the clinic data as the Program Manager of the CHS 
HIV/AIDS program. 
 
The ART initiation was based on the national guideline eligibility criteria adapted 
from WHO which required: WHO stage IV regardless of CD4 cell count and WHO 
stage I, II or III with CD4 cell count < 200. In addition, a number of social criteria 
needed to be met such as fixed address for > 3 months in the area, readily accessible 
follow up site, absence of substance abuse and psychiatric illness and commitment to 
lifelong medication.  
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3.3. Sampling 
 
The sampling frame includes all eligible patients that started HAART in Nyangana 
District between August 2004 (official launch of the program) and end of April 2006. 
This allowed a follow up period that ranged between 12 and 32 months in an intention 
to treat analysis. The sample attrition related to death, transfer out of the district and 
lost to follow up during this period will be considered in analysing treatment outcome 
and survival on HAART of this cohort. 
Inclusion criteria 
? All HIV/AIDS adult patients who were initiated on HAART in Nyangana 
ART clinic as treatment naïve 
?  HAART must have been initiated between August 2004 and April 2006 (a 
minimum of one year enrolment prior to the time of analysis regardless of 
outcome) 
? Patient outcome must be documented (alive, died, lost to follow up or 
transferred out) 
Exclusion criteria 
? Children < 13 years 
Therefore, of the total 590 patients enrolled on ART from August 2004 to April 2006, 
281 adult patients met our inclusion criteria and qualified for the present analysis. In 
the interest of homogeneity of analysis and of the time at hand, the investigator has 
chosen to analyse only adult data. The following schema describes how the patient 
selection was done:  
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Total patients enrolled on ART 
from August 2004 to April 2007: 
Total site cohort 
Total patients enrolled in ART for a 
minimum of 1 year as of April 07, regardless 
of outcome: corresponding to total as of 
April 06 
Figure 2: Sampling selection flow 
 
Transferred out: 
23 
281 adults 
(91.5%) 
26 children 
(8.5%) 
Total enrolled as of 
April 06: 307  
Total ever enrolled on 
ART as of April 07: 590 
Lost to follow 
up: 12 
Died: 102 Treatment 
stopped: 3 
Alive and on ART 
as of April 07: 450 
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3.4. Data collection 
Data source 
This is an operational study using a retrospective data enquiry from standardised 
patient files and registers used in the ART clinic in Nyangana. Theses data are 
regularly captured as part of a routine paper-based patient record system. It contains a 
number of variables (numerical and categorical) ranging from demographic to clinical 
and pharmacological information as recommended by WHO patient monitor system. 
The variables abstracted were sex, age, marital status, pregnancy status, date started 
ART, TB status at therapy initiation, baseline and subsequent reading (6, 12, 18, 24 
months) of weight/BMI, CD4 cell count, WHO clinical stage (I, II, III, IV), functional 
status (Working, Ambulatory, Bedridden) (WHO, 2006). Adherence level was also 
abstracted as patient files indicated a routine collection of the last 28 days self 
reported adherence during clinic visits. The duration on ART by April 2007, the date, 
cause and place of death, the date of loss to follow up or transferring out as well as 
ARV regimens prescribed were additional variables, all of which were entered in an 
excel database by a trained data clerk. For patients who died while on ART, we relied 
on hospitalisation records and reports from field workers who conduct regular home 
visits to trace defaulters. 
 
For the purpose of data quality assurance, after data abstraction and coding in an excel 
database, data cleaning was done by checking row by row searching mainly for range, 
transcription errors (e.g. CD4 cells in wrong field), inconsistencies (e.g. male with 
pregnancy status yes) and omissions. Every finding was traced back to the original 
patient file for validation. The use of excel advanced filter and the frequencies 
distribution in EPI Info proved very useful in identifying percentages and outliers. 
3.5. Data analysis 
Using adapted modelling approach from Stover et al. (2006) and personal 
communication from Professor Van Damme and Dr Ludwig Apers in a discussion at 
the Institute of Tropical Medicine in Antwerp (W. Van Damme & L. Apers, pers 
comm, Sept 2006), we estimated the population living with HIV/AIDS (based on 
district population and prevalence) and those in need of treatment at the start of the 
program and subsequent yearly intake. These approaches for estimate are based on 
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EPP and Spectrum models. Demographic characteristics (age, sex) were analysed 
through descriptive statistics. 
 
Treatment outcome, baseline and follow up clinical and immunological data entered 
into an Excel database were analysed using EPI info 2000 or SPSS. The frequency 
distribution of patients on ARV by CD4 cell count categories and weight at baseline 
and at 6, 12, 18, 24 months was done. 
 
The following computations were used: measures of central tendency (mean, median), 
measure of dispersion (range, standard deviation) for all parameters of interest (CD4 
cell count, weight/BMI). Though WHO generally recommends the use of median as 
CD4 is usually not normally distributed, the specific distribution of CD4 cell count for 
each analysis (obtained through normality test) will determine the use of either mean 
or median. In addition, a paired comparison test of the change in CD4 cell count and 
weight/BMI from baseline and at 6, 12, 18 and 24 months duration on ART cross-
tabulated to gender was conducted.  
 
Patients who died during the study period were analysed with regards to possible 
cause of death, duration on ART before death and place of death. With death as event 
of interest, SPSS Kaplan-Meier probability of survival was calculated censoring for 
loss to follow up and transferred out. 
 
Using a multivariate Cox regression analysis, the investigator went beyond the 
primary descriptive level to gain insight into the effect on survival of baseline 
parameters such as WHO staging, performance scale, weight, BMI, CD4 count and 
sex. 
3.6. Reliability and Validity 
Simplified ART cohort analyses are becoming standard practice and are currently 
recommended by WHO through longitudinal patient monitoring system. This includes 
careful follow up of enrolled patients at specific intervals, careful recording of 
minimum monitoring data and analysis of different assigned cohorts based on defined 
outcome. The sample size that includes all PLWHA who have enrolled and attended 
ARV care during the period under study in this district will provide a high level of 
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internal validity as no selection bias is expected. The cohort analysis approach is 
replicable in any ART site within the country. Generalizability of the results will be 
limited because clinical and immunological responses to ART may vary according to 
many other variables including the prevalence and maturity of the HIV/AIDS 
epidemic, the disease co-morbidity profile, adherence profile, the socioeconomic 
conditions (the Nyangana population is mainly a rural community) and models of 
ART delivery (e.g. entry to care requirements, follow up system). The Nyangana ART 
program has been built on strong reporting requirements of an international donor 
agency which demands high quality of data. As a result, data quality verification and 
system assessment have been regularly done in this site. 
3.7. Limitations/Assumptions 
This is mainly an observational study based on secondary analysis of routine data. 
Despite considerable efforts of data cleaning and validation, some incorrect entries 
and missing values might affect our analysis. Furthermore, the confounding effect of 
some unmeasured variables such as individual uptake and timing of treatment 
initiation, individual level of adherence, relative potency of different regimens used 
and more especially failure to validate clinical and immunological outcomes with 
viral load testing could constitute serious limitations in this study. 
 
It is further assumed that the CD4 cell count machine provides results within 
appropriate reference ranges and that the coefficient of variation is not too large to 
affect the analysis. 
3.8. Ethical statement 
The study is non experimental, fundamentally based on record review and does not 
involve human participants or animal experiment. Therefore, no harm to human 
subjects is foreseeable and no consent is required in the execution of this study.  
 
However, to protect patient identity and ensure total confidentiality, records entered 
into the database were done anonymously using unique patient codes that made it 
difficult to trace the patient whose data is being analysed. The investigator who was 
the Chief Medical Officer and national coordinator of the program enjoyed high 
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credibility in the ART clinic and made use of the existing routine data captured by the 
local team to abstract the necessary variables for analysis. 
 
After approval by the UWC Higher Degrees Committee, the proposal was also 
approved by the Namibian MoHSS Bio-Medical Ethics Research Committee. 
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Chapter 4. Results 
 
4.1. Baseline characteristics 
Our study population includes all treatment naïve adult patients, enrolled in HAART 
during period August 2004 (programme launch) to April 2006 at Nyangana ART 
clinic. Of the cumulative total 590 patients ever started by April 2007, 307 patients 
(52%) qualified for entry of which 281 were adults (91%) and 26 were children (9%). 
As stated in the methodology, in the interest of homogeneity and time, only data from 
adult age group defined in our programme as aged 13 years and older were analysed. 
The results are based on observed, recorded data. There was no imputation for 
missing values and therefore “n” will vary depending on each variable analysed. 
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4.1.1. Demographic characteristics 
Table 1: Demographics 
 
 
 
 
 
 
 
 
 
 
 
 
Variables 
 
 
 
Standard 
Deviation 
 
 
Mean difference 
 
Sex 
Male 
Female 
 
Age (years) 
Mean (all) 
       Male 
       Female 
Minimum (all) 
Maximum (all) 
Age group (years) 
   15-24  
   25-34 
   35-44 
   >=45 
 
Employment status 
Employed 
Unemployed 
 
Marital status 
Single 
Married 
Divorced 
Widow(er) 
 
 
 
 
 
n=281 
87(31%) 
194(69%) 
 
n=280 
36.1 
40.3 
34.3 
16 
77 
n=280 
27(9.6 %) 
98(35%) 
109(38.9%) 
46(16.4%) 
 
n=281 
41(14.6%) 
240 (85%) 
 
n=281 
80(25.5%) 
130(46.3%) 
28(10%) 
45(15.3%) 
 
 
 
 
 
 
 
 
 
 
9.4 
9.9 
8.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Between males and 
females(F=26.4, p-
value<0.0001) 
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4.1.2. Estimation of ART coverage in Nyangana Hospital 
Using available measure of estimates, public health practitioners continuously attempt 
to calculate the coverage of ART in order to put in place strategies geared towards 
access for all by 2010. It is currently estimated that ART is reaching 46% of those in 
need in Nyangana district). 
 
Table 2: Estimate ART coverage in Nyangana district 
 
Total district population  41,000
Estimated adult population (15-49) 45% 18,450
HIV prevalence in 2004 (beginning of ART) 18%
Estimated number PLWHA in 2004 (18% of 18,450) 3,321
Estimated number in need of ART at start (15% of 
3,321) 
498
Projected number in need second year: survival of first 
year (85% of 498) + 10% of estimated PLWHA 
755
Projected number in need third year: survival of second 
year (85% of 755)+10% of estimated PLWHA 
973
Total receiving treatment by end of April 07 (32 months) 450
% PLWHA receiving  ART vs those in need 46%
 
4.1.3. Duration on HAART 
We set to include data from patients with a minimum of 1 year on HAART to allow 
for trend analysis. This meant including patient who enrolled and initiated treatment 
between the launch of the ART program in August 2004 until April 2007 regardless 
of their outcome. By then, the overall mean duration on treatment is 16.5 months with 
range between 1 week (for those who died) and 32 months (for those alive). The 
stratified means are 5.1 and 20.8 respectively for those who died and those still alive.  
 
4.1.4. Clinical baseline characteristics 
The following baseline parameters were recorded: Weight, Height, BMI, WHO 
staging, functional status, and presence of TB or not. 
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Table 3: Clinical baseline characteristics 
 
 
 
Variables at baseline 
 
 
 
Standard 
Deviation 
 
 
Difference 
 
Weight (kg) 
Mean (all) 
    Male 
    Female 
 
BMI 
Mean (all) 
       Male 
       Female 
 
WHO clinical stage 
Stage I 
Stage II 
Stage III 
Stage IV 
 
Functional status 
Working 
Ambulatory 
Bedridden 
 
TB status 
Yes 
No 
 
Pregnancy status 
Yes 
No 
 
Baseline regimen 
D4T-3TC-NVP 
D4T-3TC-EFV 
AZT-3TC-NVP 
 
 
 
n=274 
48.3 
53.3 
46.1 
 
n=137 
19.4 
20 
19.2 
 
n=281 
13(4.7%) 
41(14.7%) 
185(66.5%) 
39(14%) 
 
n=281 
19(6.8%) 
197(70.1%) 
65(23.1%) 
 
n=281 
71(25.3%) 
210(74.7%) 
 
n=194 
13(6.7%) 
181(93.3) 
 
n= 281 
233(82.9%) 
40(14.3%) 
8(2.8%) 
 
 
9.6 
9.0 
9.0 
 
 
3.3 
2.4 
3.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No difference between 
male and female 
 
 
 
No difference between 
male and female 
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Data quality assurance parameters (HIVQUAL) 
In order to maintain high quality standards, an approach to quality management based 
on performance measurement and quality improvement requires measuring a number 
of indicators pertaining to patient monitoring such as how well is the weight, CD4 
count, WHO clinical stage monitored through the continuum of care or how well is 
Pulmonary TB being screened at each visit (Bruce, 2006). 
 
Of the sample being analysed, the monitoring of CD4 count and weight was evaluated 
at different time intervals for patients still in care: 
 
Table 4: Proportion of weight and CD4 cell count available at different time interval 
 
 
 
 
 
 
 
 
 
 
 
 
This table is indicative of challenges in data collection: 
? At baseline every patient had a CD4 count and 98% had a weight charted  
? An average 35% of CD4 counts were missing at each  time interval 
? An average 10% of weight measurements were missing at each time interval 
 
Time 
interval 
Expected 
Number 
at each 
interval 
CD4 measured Weight 
measured 
 
Number
 
% 
 
Number
 
% 
Baseline 281 281 100 274 98 
6 months 224 152 68 203 91 
12 months  214 138 64 194 91 
18 months 139 93 67 127 91 
24 months 80 51 65 70 88 
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Table 5: Regimen substitution/switch 
__________________________________________________________________ 
Substitution/switch (n=281) 
___________________________________________________________________
   
 Yes  55(19.6%)  
 No  224(79.7%)  
 Switch  2(0.7%)  
_____________________________________________________________________ 
 
 
Per WHO definition, substitution applies to change within one regimen for whatever 
clinical indication whereas switch refers to change from the first line to the second 
line regimen (WHO, 2006). Whereas 19.6% have experienced ART regimen 
substitution, the switch to second line in this cohort only occurred in less than 1% of 
patients after 24 months on treatment. 
4.1.5. Baseline CD4 cell count 
Immunologic status at baseline was assessed by the median and mean CD4 cell count. 
Mean will be used in our further discussion as the normality test showed normal 
distribution.    
 
Table 6: Baseline CD4 count  
 
Mean   166
Median   131
Std. Deviation   124
Percentiles 25 75
  50 131
 75 216
Minimum  6
Maximum   630
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Figure 3: Baseline CD4 cell count stratified by sex 
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It appears that males were more likely to have lower median CD4 cell count (107) as 
compared to females (148), (F=14.4, p value <0.0001).  
 
An additional illustration of CD4 cell count distribution by sex is shown below. More 
than 80% of males had CD4 cell count less than 200 cells/µL compared to 50% of 
females.   
The majority of patients (72.6%) were initiated on HAART within the nationally 
recommended cut off of less than 200 cells, indicative of good adherence to the 
national guideline. It appears that females were more likely to have higher CD4 count 
as compared to males. 
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Figure 4: CD4 cell count at ART initiation by sex 
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CD4 cell count IQR: 75-216 
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4.1.6. Follow up parameters 
Weight 
The change in weight over the treatment period, ignoring missing values at different 
time intervals is as follows: 
 
Figure 5: Mean weight at follow up intervals  
 
Mean weight from baseline
48
54
55
56
56
40 45 50 55 60
0 month
12 months
24 months
M
on
th
Weight (Kg)
weight
weight 48 54 55 56 56
0 month 6 12 18 24 
 
 
 
Table 7: Mean weight  
 
Encounter Number Mean 
weight 
(kg) 
SD Mean 
difference 
(Kg) 
Baseline 274 48.4 9.7 - 
6-month 203 54.0 9.3 +5.6 
12-month 194 55.5 9.8 +7.2 
18-month 127 56.4 8.9 +8.1 
24-month 70 56.0 8.5 +7.7 
 
 
Most weight gain was observed in the first 12 months and then it appears to increase 
only slightly subsequently.  
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Functional status 
Table 8: Progression of functional status at follow up  
 
 
    Baseline 6 months 12 months 24 months 
WHO functional status (n=280) (n=215) (n=208) (n=66) 
 Working  19(6.8%) 16(7.4%) 43(20.7%) 45(68.2%) 
 Ambulatory  197(70.4%) 196(91.2%) 164(78.8%) 21(31.8%) 
 Bed-ridden  64(22.9%) 3(1.4%) 1(0.5%) 0 
_____________________________________________________________________ 
 
CD4 cell count response 
The median CD4 count record at various follow up period defines the immunological 
recovery observed during ART. The median CD4 cell count recorded at different 
intervals using only available values showed an increase from baseline of 158 and 206 
cells respectively at 6 and 12 months. 
 
Figure 6: Median CD4 cell count at follow up intervals  
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Table 9: Median CD4 cell count increase 
 
Encounter Number 
of 
patients 
Median 
CD4 
count 
IQR Median 
increase 
Baseline 281 131 75-216 - 
6 months 152 289 194-425 +158 
12 months 138 337 232-492 +206 
18 months 95 362 234-517 +231 
24 months 51 422 268-542 +291 
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There were only 33 patients who had CD4 count values at each follow-up time. They 
showed CD4 cell count gain of 136 and 217 cells respectively at 6 and 12 months 
 
Table 10: CD4 distribution per range during follow up intervals 
 
   Baseline 6 months 12 months 24 months 
   (n=281) (n=152) (n=138) (n=51)  
0-99   36.1%  2.6%  5%  4% 
100-199  36.5%  24%  13%  7.8% 
>=200   27.4%  73.4%  82%  88.2% 
_____________________________________________________________________ 
 
Adherence profile 
Based on self-reporting of number of pills missed during the last 28 days as 
documented in the patient file at the time of data collection, available data classified 
242 patients into the following categories:  
Good (missed 3 doses or less)  201(76.7%) 
Fair (missed 4 to 8 doses)   33 (12.6%) 
Poor (missed 9 doses or more)  28 (10.7%)  
This dataset showed an association between level of adherence and being alive or 
dead.  
 
Table 11: Association between adherence level and treatment outcome 
 
 
 
 
 
 
 
 
 
 
 
OR 2.4 (95% CI: 1.17-5.28), p-value=0,008 
Those who died were twice as likely to have fair or poor adherence as compared to 
those who survived. 
Adherence Died Alive Total 
Fair or poor 17 35 52 
Good 31 159 190 
Total 48 194 242 
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4.1.7. Mortality on HAART 
This cohort showed that 66 (23.5%) people died on ART. Mortality was higher 
amongst males as compared to females (chi square 4.42 p-value=0.035) suggesting 
that the odds of dying is 1.87 times greater among males as compared to females. 
Table 12: Died by sex distribution 
Sex Number 
 
Died 
 
% 
Male 87 26 29.9 
Female 194 40 20.6 
Total 281 66 23.5 
 
More than 60% died within first 3 months and close to 80% within first 6 months. 
Table 13: Distribution by time of death 
Month Died % 
0-3 months 40 60.6 
4-6 months 12 18.2 
7-12 months 7 10.6 
13-24 months 7 10.6 
Total 66 100 
 
Figure 7: Distribution by cause of death 
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4.1.8. Survival analysis 
 
Overall survival 
 
Figure 8: Overall survival on ART by 32 months 
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Survival by sex 
 
Figure 9: Survival on ART by 32 months by sex 
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At 32 months, the probality of survival was 0.65 for males and 0.75 for females. 95% 
CI (21-26). This difference is stastically significant (log rank 2.7, p-value=0.05) 
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Figure 10: survival stratified by sex and CD4 count group 
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In the CD4 cell count group less than 100, females have much better survival than 
males. (log rank, p-value=0.029) 
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Survival by baseline CD4 cell count 
Figure 11: Survival on ART stratified by baseline CD4 count 
Duration by April 2007 (in months)
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At 32 months, the probability of survival was 0.82 for patients with median CD4 cells 
count  between 101 and 200 and 0.65 for those with CD4 cells count less than 100 
 
Table 14: Cox regression analysis: association between baseline variables and 
survival 
 
 
VARIABLES B SE WALD DF SIGNIFI
CANCE  
EXP (B) 
(HR) 
95% CI FOR 
EXP(B) 
Lower Upper 
Sex 0.834 0.334 6.234 1 0.01 2.302 1.196 4.430 
Weight -0.051 0.022 5.232 1 0.02 0.951 0.910 0.993 
Functional status -0.741 0.298 6.182 1 0.01 0.477 0.266 0.855 
 
281  Total cases read 
         8  Cases with missing values 
         0  Valid cases with non-positive times 
         0  Censored cases before the earliest event in a stratum 
 
 
 
 
 39 
       8  Total cases dropped 
     273  Cases available for the analysis ( all baseline variables were included with 
weight in Kg as continuous variable and functional status collapsed in binary 
variable). 
  
The following baseline variables were associated with shorter survival: male sex 
(women were twice as likely to survive as compared to males), lower body weight 
(those with lower body weight in Kg were less likely to survive), functional status 
(those with fucntional status ambulatory and bed redridden were less likely to survive 
as compared to those with working status). In this data set, the likelihood of survival 
does not depend on age. 
 
4.2. Discussion 
The present study has been one of the very few research endeavours to capture 
longitudinal data on patients receiving ART in Namibia. Some unpublished cohort 
analyses have been conducted in a couple of district hospitals in Namibia. The 
investigator set out to assess the effectiveness of the Nyangana District ART 
programme by analysing clinical and immunological response as well as survival 
pattern of patients enrolled since the launch of the programme in August 2004 until 
April 2006. The following is a discussion of the findings in line with the research 
question and the study objectives. 
 
Estimation of ART coverage 
Based on the modelling used, ART in Nyangana District is estimated to be currently 
reaching 46% of those in need of it.  Despite the limitations associated with this 
estimation approach, it provides a reasonable basis and a tool for programmatic 
decision making. 
 
Compared to the Global and African region average of 28% (WHO, UNAIDS, 2007), 
it would appear that the Nyangana District HIV/AIDS programme is well on the road 
towards access for all. Compared to 2 years ago, the figure also represents an 84% 
increase from the national average announced by the Minister of Health when he 
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declared that Namibia was amongst the only three SSA countries to provide ART to 
more than 25% of those in need of it (The Namibian, 2005).  
 
Demographics characteristics 
The feminisation of the HIV/AIDS epidemic is apparent in this study with 69% of the 
281 enrolled in ART being females. This is generally in agreement with many 
findings across SSA that have shown the proportion of ART clients who are women 
being in the range of 60 to 75%. South Africa has a worse gender inequity as findings 
indicate up to 76% of ART clients are female in one study (Ferradini, 2006; Venter, 
2004; MSF, 2003, BMS, 2006). Although women bear the brunt of the disease 
comprising 61% of PLWHA in SSA (UNAIDS, 2007), a number of favourable factors 
related to better health seeking behaviour, lower level of stigma and availability of 
PMTCT services seem to play a role in their acceptance and access to ART 
programmes compared to men. The general poor male involvement reported in many 
studies and HIV/AIDS programmes has prompted a campaign in Namibia to address 
gender norms that might result in better utilisation of HIV-related clinical services for 
men. 
 
The mean age at treatment initiation was found to be 36 years, with the minimum and 
maximum at 16 and 77 years respectively. The majority (90.3%) were aged 25 years 
and above (Table 1). This is suggestive of an HIV infection occurring in the late teen 
ages/earlier twenties, amongst the most sexually active, with the need for treatment 
emerging only 8 to 10 years later. The mean age is similar to several other studies 
which found mean age to be 37 years (Philips, 2001; BMS, 2006). A Malawian study 
indicated a median of 34.9 years whereas an even lower mean age of 31 years was 
reported in the MSF cohort in Khayelitsha (Ferradini,et al., 2006; MSF, 2003).    
 
An interesting finding was the mean age disaggregated by sex. It shows a statistically 
significant difference with males having a mean age higher (40 years) than females 
(34 years) (p<0.0001). This is found across all studies reviewed and more especially 
in the BMS multicentre analysis. Explanation for this could not be found. Older age at 
HIV acquisition in males as well as poor health seeking behaviour amongst men as 
they wait long before accessing care and treatment are the leads to be explored.  
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Most ARV users in this study population were unemployed (85%). The current 
unemployment rate in Namibia stands at around 30%. However, in rural communities, 
including the catchment population of the ART centre in this study, higher 
unemployment rates have been noted resulting in poverty and lack of food security.   
 
Clinical baseline characteristics 
The table 3 displays a number of clinical measures obtained at baseline. The mean 
weight and BMI were respectively 48 kg and 19.4. This body weight was significantly 
lower than 57 kg reported by MSF (2003) in their Khayelitsha cohort. Genetic and 
ethnographic differences might account for these differences. Food security can not be 
ruled out as these are two different communities of which one is rural (Nyangana) and 
the other one urban (Khayelitsha). When compared to the BMS multicentre analysis, 
our mean weight is still lower than the range of 55.4 to 61.2 Kg. Similarly, the mean 
BMI of 19.4 is also lower than 19.7 reported by Moore in Uganda (2007) in Uganda. 
It can therefore be assumed that a general trend of lower mean body weight and BMI 
is observed at treatment initiation in our cohort. An implication of this could relatively 
higher mortality rate as observed in our cohort (Moore, 2007).  
 
The classification of patients at baseline into WHO clinical stage revealed another 
important finding. More than 80% of patients were stage III and IV (advanced and 
severe disease) as compared to 55.9% in an MSF study (2004) and 39% in the study 
by Moore et al (2007). This is indicates that patients in this study were more likely to 
enter ART care with advanced immune suppression. This trend was observed despite 
availability of voluntary counselling and testing services in the district. However, as 
this was an earlier cohort enrolled in ART care in the first two years of the 
introduction of ART programme in this community, it is likely that this tendency 
might have been reversed. Stigma and discrimination that hampered the scale up of 
ART in its earlier days was wearing off as the success of therapy became apparent in 
most communities. 
 
A strong relationship exists between functional status and WHO clinical stage. As 
most patients had advanced to severe HIV disease, it was expected that their 
functional status would be also unfavourable. This was confirmed by the finding that 
more than 90% in our patient population had a functional status either ambulatory or 
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bedridden. With 23% in the bedridden status, it indicates a high loss of productivity 
and poor quality of life associated with advanced disease stage. 
 
With regards to TB screening, 25.3% of patients were found to have TB at ART 
initiation. This is more than twice the 11% reported by the study done by Libamba et 
al.(2006) in Malawi. Although efforts were being made to screen for TB at baseline 
there was no measure of how many patients were actually screened. A tool to capture 
TB screening and diagnosis at each care visit is important in these settings where 
HIV/TB co-infection is more than 65%. This view is supported by WHO’s team of 
experts who recommends that high TB/HIV co-morbidity in many countries requires 
effective coordination, referral and integrated monitoring and evaluation of the two 
programmes (WHO, 2006). 
 
ART regimen 
At baseline, all 281 patients included in our study were initiated on the first line 
regimen recommended by the National guideline (Table 3). This is indicative of a 
high level of standardization and compliance in the public sector in Namibia. It falls 
in line with the WHO public-health approach to providing ART in resource limited 
settings. A similar compliance was reported in the Khayelitsha cohort (MSH, 2004) 
with a difference that the EFV based regimen there (because of TB) was 60% as 
compared to our 14.3%. With less than 1% switching to second line therapy by 24 
months comparable to Libamba et al (2006) findings, the Nyangana ART programme 
presents a good prospect of a lasting first line therapy. However, without regular viral 
load monitoring, this finding should be taken with caution and requires further 
investigation that will be followed up by the investigator. 
 
Data quality assurance 
The fact that missing values were observed at each follow up period means that our 
longitudinal data analysis must be interpreted with caution as missing cases might 
differ in analytically important ways from cases where values are present. To address 
this issue we compared findings of mean CD4 cell count and body weight using 
available data to that obtained using data from patients with values at all encounters. 
All 281 patients had CD4 cells count reading at baseline and 98% had weight charted. 
However, at subsequent follow up encounters, an average 35% of CD4 cell count 
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could not be traced and around 10% of patients were missing body weight. This 
finding underscores the challenge of data collection, storage and retrieval that many 
ART sites are currently experiencing. 
 
Baseline CD4 cell count 
The immunological status at baseline in this study (median CD4 count of 131 cells/µl, 
IQR: 75-216) showed consistency with other studies as in general most patients 
entered ART care with advanced to severe immune suppression. Moore et al.(2007), 
Laurent et al. (2002) reported a median baseline CD4 count of 127 and 108 cells 
respectively. The Khayelitsha cohort found an even more profound immune 
suppression with median of 43 cells/µl. A combination of patient and provider factors 
may be at play. Awareness, motivation, level of stigma and discrimination are 
important patient factors in accessing care. On the other hand, using a cut off for 
treatment eligibility of 200 cells/µl may constitute a barrier to an optimal treatment 
initiation time. As a matter of fact, this finding should be considered as normal in 
terms of compliance with the national guideline. However, when disaggregated by 
sex, it would appear that males were more likely to have lower median CD4 cell count 
(107 cells/µl) as compared to females (148 cells/µl) (F=14.4, p-value<0.0001). This 
finding is similar to that of a recent publication from Collazos et al (2008) who found 
at a borderline statistical significance that the women’s average CD4 cell count was 
higher than men’s. They further argued that there was a general tendency of women 
having lower viral load and higher CD4 cell counts when they initiated ART as 
compared to their male counterparts. It can be speculated that some difference might 
reside in better health seeking behaviour amongst females and availability of PMTCT 
services that provide a canvassing ground for HIV positive women.  
 
Follow up parameters 
Weight 
Serial measurements of weight at baseline and follow up periods provided the basis 
for comparison. Missing values at random at different follow up periods limit the 
analysis of trend. We compared mean weight obtained in the entire cohort using the 
available dataset at each encounter to mean weight obtained among patients with 
weight measured at all encounters. In the entire cohort the weight gains from baseline 
were 5.7, 7.2, 8.1 and 7.7 Kg respectively at 6, 12, 18 and 24 months.  In the smaller 
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population with weight measurements at all visits the gains at 6 and 12 months were 
4.6 and 5.6 Kg respectively. Whichever analysis we used, these findings would appear 
to suggest similar weight gains observed in other studies.  At 6 months, the BMS 
analysis (2006) showed weight gains at different sites between 3.8 to 6.2 Kg.  The 
MSF (2003) cohort indicated a gain of 5 Kg at 6 months and 9 kg at 12 months. The 
assumption is that a good clinical response on ART will result in weight gain that 
clinicians need to monitor regularly. 
 
Functional status 
The progression of functional status from bedridden through ambulatory to working 
status (productive life) provided additional information on clinical responses to ART. 
Whereas the percentage in bedridden status decreased (22.9% to 0%), the working 
status increased (6.8% to 68.2%) indicative of health gains achieved for PLWHA 
receiving ART . This is called the “Lazarus effect” by many PEPFAR programme 
managers. Though encouraging, this result (68.2%) is lower than the 85% fit to work 
reported by Libamba et al.(2006). The longer study period and the larger sample size 
in their study might account for the difference. 
 
CD4 cell count 
CD4 cell count is the best proxy of ART effectiveness in resource poor settings. We 
have analysed in two ways to obtain the most accurate reflection. Using the available 
dataset at each encounter, we had a median cell count increase of 158 and 206 
cells/µL at 6 and 12 months, respectively. The gains for clients who had CD4 counts 
done at both 6 and 12 months were very similar - 136 and 217 cells/µL, respectively. 
Although these results differ from some published studies (Laurent et al., 2002; 
Gallant, 2003) that reported a lower increase of about 85 cells at 6 months, they are 
consistent with those of the MSF cohort (2004) in Khayelitsha which found a similar 
increase of 133 and 221 at 6 and 12 months, respectively. It is argued that in general, 
most patients on potent regimens and with good adherence will achieve a successful 
CD4 count response in the course of time. By 24 months close to 90% of patients on 
ART had a CD4 cell count above 200 cells/µl.  
 
These findings accord with our earlier observations which showed significant gain in 
weight and improvement in functional status over time.  
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There is a major limitation in these findings in that the impact of adherence level on 
all these CD4 cell count responses were not evaluated. 
 
Adherence 
Adherence is critical to the success of any ART programme. Our results are based on 
self-reported adherence and a once-off measurement enquiring on a 28-day 
medication supply. Most patients (76.7%) had an adherence rated as good by WHO 
standards and this dataset suggested a highly statistically significant association 
between adherence level and outcome. Those who died were twice more likely to 
have fair or poor self-reported adherence. (OR: 2.4, 95% CI: 1.17-5.28, p-
value=0.008). The lack of validation with other adherence measurement method and 
viral load assay testing and a correlation study to CD4 cell count response are major 
limitations in interpreting these findings. 
 
Treatment outcome 
The cumulative treatment outcome indicated retention in care of 69% (those alive and 
on ART at the analysis time). The observed attrition rate of 31% is mainly driven by a 
relatively high mortality on ART of 23.5% (This mortality represents 75.8% of the 
total attrition).  Although this mortality is comparable to that found by Ferradini et al. 
who reported 19%, it would seem to be relatively higher than most studies have 
reported. The ART-LINC cohort indicated a mortality of 4% while Libamba et al. 
(2006) had 8% in their study. It is possible that some of the studies that reported lower 
mortality had a higher loss to follow up as many patients would die at home without 
being reported as such. Active defaulter tracing and closer follow up could explain a 
relatively high reported death on ART. 
 
The cumulative retention in care of 69% (mean duration 16.5 month) observed in this 
study was above the gloomy 60% reported recently by Rosen (2007). In his 
systematic review of 32 publications in 13 African countries, he found that “since the 
inception of large-scale ART access early in this decade, ART programs in Africa 
have retained about 60% of their patients at the end of 2 years”. Compared to the 80% 
reported in the west for the same duration, Africa has still a lot to do in improving its 
model of care. 
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Mortality on HAART is higher in males than in females. Our results showed that 
29.9% of males died as compared to 20.6% of females. The odds of dying was 1.87 
times greater among males as compared to females. This was supported by the KM 
survival analysis which indicated at 24 months better survival amongst females as 
compared to males with a high level of statistical significance when stratified by CD4 
cell count group (cum survival of 0.71 vs. 0.55, log rank, p-value=0.029) and the Cox 
regression model which showed male gender associated with shorter survival (OR: 
2.30, 95% CI: 1.19-4.43, p-value=0.01). According to Collazos et al. (2007), for the 
past 2 decades there are conflicting findings on the difference between men and 
women in their response to HIV infection and treatment. 
 
In general, with only death events accounted for, the Kaplan-Meier probability of 
survival was 0.75 at 24 months. This is below the 0.81 reported by Ferradini, 2006, 
for the same duration. Cumulative survival appears lower in Nyangana cohort and 
factors such as rural population, unemployment, food security, advanced/severe 
disease at treatment initiation and the TB burden might account for this. 
 
In addition, as per the Table 14, the Cox regression analysis showed that patients with 
lower body weight and functional status of ambulatory or bedridden were less likely 
to survive. This is similar to Moore et al. (2007) whose recent study outlined that low 
CD4 cell count, low body weight, TB and anaemia were major risk factors for death 
after ART commencement.  
 
More than 60% died within the first 3 months and close to 80% within the first 6 
months of initiating ART. This is a common feature reported in several studies in 
African cohorts as cited by Laurent et al (ref). They argued that death and loss to 
follow up tend to happen in the first 6 months of ART commencement. Factors such 
as cut off CD4 cell count for treatment initiation, patients presenting at ART clinic 
with advanced to severe disease, multiple co-morbidity amongst most patients and 
earlier immune reconstitution inflammatory syndrome are cited as possible 
explanation for this prevailing situation (Laurent et al., 2006).  
 
The main causes of death in our cohort were TB with 37.9% and gastroenteritis with 
18.2% of cases). The proportion of unknown causes of death is relatively high 
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(13.6%). Most likely related to the fact that more than 25% were reported to have died 
at home making it difficult to accurately account for their cause of death. Nonetheless, 
TB is the leading cause of death of PLWHA world wide. Our findings are in 
agreement with this reality. On the other hand, it is not surprising that gastroenteritis 
comes second as in this rural setting, limited access to safe drinking water, poor 
sanitation and poor food hygiene contribute to water borne diseases in PLWHA. 
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Chapter 5. Conclusions and recommendations 
5.1. Conclusion 
The Namibian country driven process of scaling up ART programme in view of 
achieving universal access to ART for those who need it is well underway and the 
Nyangana District ART coverage of 46% is indicative of those efforts. However, this 
access to ART is characterised by poor male involvement as demonstrated by the low 
percentage of men enrolled in ART care. Not only is their accessibility to treatment 
limited but men also present with unfavourable baseline profile (advanced disease, 
lower CD4 cell count) resulting in poor treatment outcome (higher mortality, shorter 
cumulative survival). In a multivariate analysis, mortality was associated with male 
gender, low baseline weight and poor baseline functional status. The clinical response 
to ART observed through weight gain and improved functional status as well as the 
immunological response observed through CD4 cell count gain, comparable to 
findings in other similar settings, were indicators of a successful ART treatment 
programme. High quality ART services can be implemented in a rural setting in 
Namibia despite several challenges ranging from socio-economic dynamics to data 
management issues at the ART site. 
 
5.2. Recommendations 
Based on the findings in this study, the followings are some of our recommendations: 
? Consider replicating the study in other faith-based ART sites in a multi-center 
analysis to allow comparability between these sites and consider national 
cohort analysis 
? Considerable efforts need be applied to increase male participation. Formulate 
behavioural change communication strategies and design incentives that will 
go to the root of why men do not come or ultimately come late to the ART 
clinic 
? Consider review of the optimal cut off CD4 cell count for treatment initiation 
to allow earlier initiation that is likely to reduce the mortality rate on HAART. 
Alternatively, an improved pre-ART monitoring and care might also result in 
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timely treatment initiation as patients followed up regularly can be started as 
the declining CD4 cell approaches the cut off point. 
? Further analysis on this dataset can be done to explore other factors associated 
with mortality on HAART in order to devise strategies to improve survival of 
PLWHA initiating HAART in Nyangana 
? Strengthen data quality to minimise missing values and allow use of simple 
clinical parameters such weight, functional status and WHO stage to monitor 
patient progress on ART 
? Increase use of viral load testing opportunities to ensure monitoring of 
therapy, validation of adherence and timely therapy switch when required  
? Improve adherence monitoring activities 
? Improve TB/HIV collaborative activities in order to decrease TB-related 
morbidity and mortality among PLWHA attending ART care 
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Annexure A 
Data abstraction tool 
 
The following were extracted from patients records (individual files and various 
registers) 
Record No.  _____________ 
1. Date of birth_____________ 
2. Age at HAART initiation (years) ____________                               
3. Sex:     M = 1  F=2   
4. Date of HAART initiation ___________ 
5. Quarter initiated (from August 2004): Q1=1, Q2=2, Q3=3, Q4=4, Q5=5, 
Q6=6, Q7=7, Q8=8 
6. Pregnancy status: N/A=0 Yes=1  No=2 
7. Marital status:  
- Single=1   
- Married=2  
- cohabiting=3  
- Divorced=4  
- Widow(er)=5 
8. Employment: Employed=1 Unemployed=2 
9. Weight (Kg)______________ 
10. Weight at 6, 12, 18, 24 months:___________ 
11. Height (m)______________ 
12. TB status: Yes=1 No=0 
13. Baseline WHO Clinical Stage : Stage 1=1, stage 2=2,  Stage 3=3, Stage 4= 4 
14. WHO clinical stage at 6, 12, 18, 24 months 
15. Baseline functional status:  
- Working=1  
- Ambulatory=2 
- Bedridden=3 
16. Functional status at 6, 12, 18, 24 months 
17. HAART regimen prescribed at start up:  
- D4T/3TC/EFV = 1  
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- D4T/3TC/NVP = 2 
      - AZT/3TC/NVP= 3 
18. Therapy substitution: Yes=1 No=0 
19. Therapy switch: Yes=1 No=0 
20. Adherence level:  
- Good=G 
- Fair=F 
- Poor=P 
21. Baseline CD4 cell count (cells/µl) ____________ 
22. CD4 cell count at 6, 12, 18, 24 months____________ 
23. Duration on treatment by April 2007 (month)____________ 
24. Outcome by April 2007: 
- Alive=1 
- Died=2 
- Lost to follow up=3 
- Transferred out=4 
25. If died, duration on treatment by the time of death event____________ 
26. If died, cause of death 
- TB=1 
- GE=2 
- Pneumonia=3 
- Anemia=4 
- Meningitis=5 
- Hepatitis=6 
- Others=7 
- Unknown=8 
27. if died, place of death: Hospital=1, Home=2 
 
 
 
 
 
